Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
retinal vein occlusion
Pharma
FDA denies Regeneron's bid for dosage flexibility on Eylea
The FDA has denied Regeneron's bid to stretch the administration of high-dose Eylea from a maximum frequency of every 16 weeks to every 24 weeks.
Kevin Dunleavy
Apr 21, 2025 8:45am
JPM25: Regeneron has few answers for declining sales of Eylea HD
Jan 14, 2025 10:25am
Eylea HD passes test in retinal vein occlusion, teeing up filing
Dec 18, 2024 8:20am
Roche's juggernaut Vabysmo routs analyst consensus
Apr 24, 2024 11:29am
Roche's Vabysmo snares FDA nod to treat retinal vein occlusion
Oct 27, 2023 11:07am
Roche's Vabysmo shows durability in retinal vein occlusion
Oct 10, 2023 10:21am
